Duncan Kennedy
No más puestos en curso
Fortuna: 16 485 $ al 31/03/2024
Perfil
Duncan Kennedy served as the Chief Financial Officer & Director at BTG Ltd.
from 2018 to 2019 and as the Chief Financial Officer & Executive Director at James Fisher & Sons Plc from 2021 to 2023.
Prior to these roles, he obtained an undergraduate degree from the University of Durham.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 31/12/2022 | 5 000 ( 0.01% ) | 16 485 $ | 31/03/2024 |
Antiguos cargos conocidos de Duncan Kennedy.
| Empresas | Cargo | Fin |
|---|---|---|
| JAMES FISHER AND SONS PLC | Director of Finance/CFO | 01/12/2023 |
| BTG | Director of Finance/CFO | 31/12/2019 |
Formación de Duncan Kennedy.
| University of Durham | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| JAMES FISHER AND SONS PLC | Transportation |
| Empresas privadas | 1 |
|---|---|
BTG Ltd.
 BTG Ltd. Pharmaceuticals: MajorHealth Technology BTG Ltd. is a global healthcare company, which focuses on interventional medicine that can help physicians to treat patients through minimally invasive procedures. It operates through the following segments: Product, Licensing, and Other. The firm's products include CroFab, DigiFab, Voraxage. The company was founded on December 12, 1991 and is headquartered in Farnham, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Duncan Kennedy
